Ohyama, Chikara
Kojima, Takahiro
Kondo, Tsunenori
Naya, Yoshio
Inoue, Takamitsu
Tomita, Yoshihiko
Eto, Masatoshi
Hisasue, Shinichi
Uemura, Hirotsugu
Obara, Wataru
Kikuchi, Eiji
Sharma, Padmanee
Galsky, Matthew D.
Siefker-Radtke, Arlene
Grossfeld, Gary
Collette, Sandra
Gooden, Kyna
Kimura, Go
Funding for this research was provided by:
Bristol-Myers Squibb KK
ONO Pharmaceutical Co., Ltd.
Article History
Received: 14 March 2019
Accepted: 8 April 2019
First Online: 19 June 2019
Compliance with ethical standards
:
: Chikara Ohyama, Takahiro Kojima, Yoshio Naya, Takamitsu Inoue, and Shinichi Hisasue declare having no conflict of interest. Tsunenori Kondo has received honoraria from ONO Pharmaceutical and Pfizer. Yoshihiko Tomita declares an advisory role for Novartis, Taiho Pharmaceutical, and ONO Pharmaceutical, received honoraria from Astellas, ONO Pharmaceutical, Pfizer, Sonafi Aventis, and Bristol-Myers Squibb, and received research funding from Astellas, AstraZeneca, Pfizer, and ONO Pharmaceutical. Masatoshi Eto received honoraria from ONO Pharmaceutical and Bristol-Myers Squibb, and research funding from ONO Pharmaceutical. Hirotsugu Uemura received honoraria from Bayer, AstraZeneca, Takeda, Astellas, Sanofi, Janssen, MSD, Bristol-Myers Squibb, and Pfizer, and received research funding from AstraZeneca, Janssen, Takeda, Astellas, Sanofi, Taiho, ONO Pharmaceutical, and Pfizer. Wataru Obara received honoraria from Bristol-Myers Squibb and research funding from Bristol-Myers Squibb. Eiji Kikuchi received honoraria from ONO Pharmaceutical, Kissei Pharmaceutical, ASKA Pharmaceutical, Nippon Shinyaku Taiho, Takeda, MSD, Pfizer, AstraZeneca, Astellas, and Chugai, and received research funding from MSD, Nippon Kayaku, Astellas, ONO Pharmaceutical, Chugai, Takeda, Taiho, and AstraZeneca. Padmanee Sharma owns stock in Jounce, Neon, Constellation, Oncolytics, BioAtla, Forty-Seven, Apricity, Polaris, Marker Therapeutics, Codiak, ImaginAb, and Hummingbird, reports an advisory role in Constellation, Jounce, Neon, BioAtla, Pieris, Oncolytics, Merck, Forty-Seven, Polaris, Apricity, Marker Therapeutics, Codiak, ImaginAb, Hummingbird, and owns a patent licensed to Jounce. Matthew D. Galsky received research funding from Bristol-Myers Squibb, Genentech, AstraZeneca, and Merck. Arlene Siefker-Radtke reports an advisory role for Nektar Therapeutics, Janssen Biotech, Bavarian Nordic, Merck Sharp and Dohme, and Seattle Genetics, and research funding from Janssen, Takeda, Nektar Therapeutics, and Bioclin. Gary Grossfeld reports employment at Bristol-Myers Squibb and owns stock in Bristol-Myers Squibb. Sandra Collette reports employment at Bristol-Myers Squibb. Kyna Gooden reports employment at Bristol-Myers Squibb and owns stock in Bristol-Myers Squibb. Go Kimura received honoraria from ONO Pharmaceutical, Bristol-Myers Squibb, Novartis, Bayer, and Chugai.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study